| scholarly article | Q13442814 |
| P356 | DOI | 10.3390/IJMS20061483 |
| P953 | full work available at URL | https://www.mdpi.com/1422-0067/20/6/1483 |
| P932 | PMC publication ID | 6472057 |
| P698 | PubMed publication ID | 30934534 |
| P50 | author | Filippo Casoni | Q55447475 |
| Paolo Fava | Q61079668 | ||
| Ottavio Cremona | Q88958887 | ||
| Paola Savoia | Q91122223 | ||
| P2093 | author name string | Ottavio Cremona | |
| Paola Savoia | |||
| Paolo Fava | |||
| Filippo Casoni | |||
| P2860 | cites work | Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions | Q21004109 |
| Recurrent BRAF mutations in Langerhans cell histiocytosis | Q24594344 | ||
| Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib | Q24594790 | ||
| Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma | Q24597152 | ||
| A landscape of driver mutations in melanoma | Q24603357 | ||
| The Ras protein superfamily: evolutionary tree and role of conserved amino acids | Q24603374 | ||
| Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma | Q24607661 | ||
| Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 | ||
| Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations | Q24632064 | ||
| Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity | Q24652600 | ||
| Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis | Q24791830 | ||
| Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells | Q26740953 | ||
| Regulation of Small GTPases by GEFs, GAPs, and GDIs | Q26825750 | ||
| FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation | Q26853282 | ||
| Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment | Q27313653 | ||
| RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth | Q27659493 | ||
| Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers | Q27685364 | ||
| Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation | Q27696239 | ||
| Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers | Q27702093 | ||
| RAF inhibitors that evade paradoxical MAPK pathway activation | Q27702299 | ||
| Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development | Q27705339 | ||
| Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAFV600E Conformation | Q27727954 | ||
| MEK1 mutations confer resistance to MEK and B-RAF inhibition | Q27777362 | ||
| Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling | Q27851628 | ||
| Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. | Q27851801 | ||
| Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial | Q27851852 | ||
| MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study | Q27852083 | ||
| Combined vemurafenib and cobimetinib in BRAF-mutated melanoma | Q27853076 | ||
| Improved overall survival in melanoma with combined dabrafenib and trametinib | Q27853091 | ||
| Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance | Q27853210 | ||
| Inhibition of Mutated, Activated BRAF in Metastatic Melanoma | Q27860458 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Epigenetic regulation in human melanoma: past and future | Q28085681 | ||
| Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF | Q28251989 | ||
| Mutational Status of NRAS and BRAF Genes and Protein Expression Analysis in a Series of Primary Oral Mucosal Melanoma. | Q51163338 | ||
| Clinicopathologic findings and BRAF mutation in cutaneous melanoma in young adults. | Q51165363 | ||
| Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies | Q52617939 | ||
| Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT). | Q52660928 | ||
| Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial | Q52686844 | ||
| Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors | Q52691585 | ||
| B-Raf inhibition in conjunctival melanoma cell lines with PLX 4720. | Q52862588 | ||
| RAS-mediated oncogenic signaling pathways in human malignancies | Q53177292 | ||
| Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma | Q53391786 | ||
| The p21 ras C-terminus is required for transformation and membrane association | Q53551139 | ||
| Analysis of BRAF mutation in primary and metastatic melanoma | Q53662079 | ||
| Role of HGF-MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer | Q53711253 | ||
| Clinical and pathological associations of the activating RAC1 P29S mutation in primary cutaneous melanoma | Q53777162 | ||
| Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial | Q53835279 | ||
| Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer. | Q54115748 | ||
| High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. | Q54491866 | ||
| First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. | Q54499836 | ||
| Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. | Q54549143 | ||
| NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. | Q54570448 | ||
| Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. | Q54587263 | ||
| N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK632) Promotes Inhibition of BRAF through the Induction of Inhibited Dimers. | Q54979742 | ||
| Roles of UVA radiation and DNA damage responses in melanoma pathogenesis. | Q54983880 | ||
| Melanoma | Q56428909 | ||
| MEK inhibitors for the treatment of NRAS mutant melanoma | Q56889985 | ||
| Melanoma | Q57571848 | ||
| BRAF and NRAS Mutations Are Frequent in Nodular Melanoma but Are not Associated with Tumor Cell Proliferation or Patient Survival | Q57664873 | ||
| PTPN11 plays oncogenic roles and is a therapeutic target for BRAF wild-type melanomas | Q57793312 | ||
| Genetic profiling of melanoma in routine diagnostics: assay performance and molecular characteristics in a consecutive series of 274 cases | Q57811152 | ||
| Structural snapshots of RAF kinase interactions | Q58086597 | ||
| Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma | Q58547833 | ||
| Molecular Pathways in Melanomagenesis: What We Learned from Next-Generation Sequencing Approaches | Q58739937 | ||
| Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries | Q60142201 | ||
| Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy | Q60302150 | ||
| Mutation Status in Primary, Recurrent, and Metastatic Malignant Melanoma and Its Relation to Histopathological Parameters | Q61804959 | ||
| Histopathologic diagnosis of dysplastic nevi: Concordance among pathologists convened by the world health organization melanoma programme | Q67758686 | ||
| Ras mutations in human melanoma: a marker of malignant progression | Q72273795 | ||
| Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations | Q73472164 | ||
| Counterpoint: The "dysplastic" nevus: What I do and do not believe | Q85919037 | ||
| Outcome of patients with de novo versus nevus-associated melanoma | Q86092362 | ||
| Sun exposure and skin cancer, and the puzzle of cutaneous melanoma: A perspective on Fears et al. Mathematical models of age and ultraviolet effects on the incidence of skin cancer among whites in the United States. American Journal of Epidemiology | Q88010143 | ||
| Improving classification of melanocytic nevi: Association of BRAF V600E expression with distinct histomorphologic features | Q88352617 | ||
| Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers | Q88669750 | ||
| Ultraviolet radiation-mediated development of cutaneous melanoma: An update | Q89219267 | ||
| Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models | Q89478898 | ||
| Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling | Q90211585 | ||
| MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology | Q90403050 | ||
| Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib | Q90864245 | ||
| Brain Distribution and Active Efflux of Three panRAF Inhibitors: Considerations in the Treatment of Melanoma Brain Metastases | Q90949397 | ||
| Targeting oncogenic Raf protein-serine/threonine kinases in human cancers | Q91004972 | ||
| Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations | Q91085244 | ||
| Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis | Q91321632 | ||
| Targeting ERK1/2 protein-serine/threonine kinases in human cancers | Q91834485 | ||
| Analysis of the B-RafV600E mutation in cutaneous melanoma patients with occupational sun exposure | Q37588790 | ||
| Dual-specificity phosphatase 5 controls the localized inhibition, propagation, and transforming potential of ERK signaling | Q37598950 | ||
| The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma | Q37626102 | ||
| NRAS mutant melanoma: biological behavior and future strategies for therapeutic management | Q37689575 | ||
| The genesis of tyrosine phosphorylation | Q37718124 | ||
| Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities. | Q37737945 | ||
| BRAFV600E: implications for carcinogenesis and molecular therapy | Q37851238 | ||
| RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy | Q37947586 | ||
| Genetic alterations of PTEN in human melanoma | Q37955107 | ||
| The Role of the PI3K-AKT Pathway in Melanoma | Q37997546 | ||
| Mechanism and consequences of RAF kinase activation by small-molecule inhibitors | Q38197024 | ||
| Dragging ras back in the ring | Q38197825 | ||
| Update on primary mucosal melanoma. | Q38210789 | ||
| Intrinsic and acquired resistance to MEK1/2 inhibitors in cancer | Q38238605 | ||
| Profile of selumetinib and its potential in the treatment of melanoma | Q38256348 | ||
| GNAQ and GNA11 mutations in uveal melanoma. | Q38258992 | ||
| The melanoma revolution: from UV carcinogenesis to a new era in therapeutics. | Q38270141 | ||
| BRAF and MEK inhibition in melanoma. | Q38342905 | ||
| Compromised MAPK signaling in human diseases: an update | Q38359194 | ||
| A compendium of ERK targets | Q38373402 | ||
| Treatment of NRAS-mutant melanoma. | Q38386344 | ||
| Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine | Q38431409 | ||
| Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer | Q38491964 | ||
| Dysplastic nevus: Fact and fiction | Q38513645 | ||
| Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis | Q38533700 | ||
| MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road | Q38591835 | ||
| NRAS-mutant melanoma: current challenges and future prospect | Q38598958 | ||
| Mutations in the promoter of the telomerase gene TERT contribute to tumorigenesis by a two-step mechanism | Q38619216 | ||
| Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond | Q38634557 | ||
| Binimetinib for the treatment of NRAS-mutant melanoma. | Q38636033 | ||
| Targeting the Ras palmitoylation/depalmitoylation cycle in cancer | Q38669156 | ||
| A review of binimetinib for the treatment of mutant cutaneous melanoma | Q38674107 | ||
| MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors | Q38679954 | ||
| Selumetinib Inhibits Melanoma Metastasis to Mouse Liver via Suppression of EMT-targeted Genes | Q38717224 | ||
| Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro | Q39936278 | ||
| Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma | Q40319765 | ||
| Genomic Characterization of Dysplastic Nevi Unveils Implications for Diagnosis of Melanoma. | Q40455273 | ||
| Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial | Q40875359 | ||
| Paradoxical activation of Raf by a novel Raf inhibitor | Q40939473 | ||
| DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers. | Q41070178 | ||
| Primary HPV test screening in cervical cancer: a two-year experience of a single screening center in Latina (Italy). | Q41171788 | ||
| A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status | Q41311583 | ||
| Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells | Q42478581 | ||
| Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity? | Q42819175 | ||
| Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma | Q43242901 | ||
| Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial | Q44442912 | ||
| Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma | Q45124043 | ||
| Farnesyltransferase-Mediated Delivery of a Covalent Inhibitor Overcomes Alternative Prenylation to Mislocalize K-Ras. | Q46078887 | ||
| The Genetic Evolution of Melanoma from Precursor Lesions | Q46079642 | ||
| Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study | Q46319029 | ||
| The PI3K Pathway in Human Disease | Q46546002 | ||
| Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study | Q46570875 | ||
| Ral signaling pathway in health and cancer. | Q47124416 | ||
| RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer | Q47340259 | ||
| Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives. | Q47375181 | ||
| Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine | Q47392574 | ||
| Trajectories of premalignancy during the journey from melanocyte to melanoma. | Q47605767 | ||
| New perspectives for targeting RAF kinase in human cancer. | Q47688064 | ||
| Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. | Q47824495 | ||
| New Drug Combination Strategies in Melanoma: Current Status and Future Directions. | Q47881317 | ||
| Melanocytic nevi and non-neoplastic hyperpigmentations | Q48614143 | ||
| Recommendations for a nomenclature system for human gene mutations. Nomenclature Working Group | Q48771295 | ||
| Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma. | Q49887930 | ||
| Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib). | Q49912368 | ||
| Epigenetics of malignant melanoma. | Q50091675 | ||
| Roads to melanoma: Key pathways and emerging players in melanoma progression and oncogenic signaling | Q38722722 | ||
| Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma | Q38727030 | ||
| An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling | Q38752000 | ||
| Next-Generation Sequencing to Guide Treatment of Advanced Melanoma | Q38754313 | ||
| Somatic driver mutations in melanoma. | Q38764368 | ||
| Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study | Q38802138 | ||
| Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study | Q38819416 | ||
| Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next? | Q38845962 | ||
| Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients. | Q38942785 | ||
| Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma | Q38953667 | ||
| Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma | Q38964277 | ||
| Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study. | Q39043736 | ||
| Whole-genome landscapes of major melanoma subtypes. | Q39060449 | ||
| KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma | Q39078976 | ||
| A mini-review of c-Met as a potential therapeutic target in melanoma | Q39096746 | ||
| MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition. | Q39120374 | ||
| The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition. | Q39124064 | ||
| Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients | Q39135886 | ||
| Melanocytic naevi with globular and reticular dermoscopic patterns display distinct BRAF V600E expression profiles and histopathological patterns | Q39157527 | ||
| Clinical Pharmacokinetics of Vemurafenib | Q39159365 | ||
| Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors | Q39161270 | ||
| Mechanisms of Drug Resistance in Melanoma | Q39169776 | ||
| Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations | Q39173195 | ||
| Post translational modifications of Rab GTPases | Q39252084 | ||
| Combination Small Molecule MEK and PI3K Inhibition Enhances Uveal Melanoma Cell Death in a Mutant GNAQ- and GNA11-Dependent Manner | Q39325158 | ||
| Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma | Q39329582 | ||
| MEK inhibitors in oncology: a patent review (2015-Present). | Q39359514 | ||
| Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated byNRASorMEKMutations | Q39385617 | ||
| RAS Proteins and Their Regulators in Human Disease | Q39407402 | ||
| Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. | Q39422587 | ||
| Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma | Q39434922 | ||
| Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate). | Q39514463 | ||
| Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial | Q39537308 | ||
| RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models | Q39692674 | ||
| Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. | Q39712781 | ||
| Both nuclear-cytoplasmic shuttling of the dual specificity phosphatase MKP-3 and its ability to anchor MAP kinase in the cytoplasm are mediated by a conserved nuclear export signal | Q28273355 | ||
| Guilty as charged: B-RAF is a human oncogene | Q28288202 | ||
| Discovery and saturation analysis of cancer genes across 21 tumour types | Q28305204 | ||
| Regulation and role of Raf-1/B-Raf heterodimerization | Q28580581 | ||
| Registered report: RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth | Q28603655 | ||
| Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials | Q28730438 | ||
| BRAF mutation predicts sensitivity to MEK inhibition | Q29614281 | ||
| Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial | Q29614756 | ||
| Highly Recurrent TERT Promoter Mutations in Human Melanoma | Q29614798 | ||
| Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion | Q29616531 | ||
| RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF | Q29616828 | ||
| Rational design of inhibitors that bind to inactive kinase conformations | Q29617558 | ||
| Improved survival with MEK inhibition in BRAF-mutated melanoma | Q29620663 | ||
| Uveal melanoma: epidemiology, etiology, and treatment of primary disease | Q30235934 | ||
| Towards Personalized Medicine in Melanoma: Implementation of a Clinical Next-Generation Sequencing Panel | Q33674041 | ||
| Prognostic and Clinicopathologic Associations of BRAF Mutation in Primary Acral Lentiginous Melanoma in Korean Patients: A Preliminary Study | Q33682137 | ||
| A highly recurrent RPS27 5'UTR mutation in melanoma | Q33917519 | ||
| Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity | Q33971120 | ||
| Somatic mutation of GRIN2A in malignant melanoma results in loss of tumor suppressor activity via aberrant NMDAR complex formation | Q34051230 | ||
| Ral activation promotes melanomagenesis | Q34086528 | ||
| High frequency of BRAF mutations in nevi | Q34160519 | ||
| Landscape of genomic alterations in cervical carcinomas | Q34169464 | ||
| Identification of Unique MEK-Dependent Genes in GNAQ Mutant Uveal Melanoma Involved in Cell Growth, Tumor Cell Invasion, and MEK Resistance | Q34272199 | ||
| Mutations induced by ultraviolet light | Q34400112 | ||
| Updates of reactive oxygen species in melanoma etiology and progression | Q34403921 | ||
| K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors | Q34427029 | ||
| The MAPK pathway across different malignancies: a new perspective | Q34459097 | ||
| Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans | Q34497490 | ||
| Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma | Q34500495 | ||
| Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis | Q34503441 | ||
| The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population-based estimate | Q34531909 | ||
| MAP kinases in the immune response | Q34542231 | ||
| Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations | Q34547540 | ||
| Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure | Q34553701 | ||
| The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells | Q34572036 | ||
| Src promotes GTPase activity of Ras via tyrosine 32 phosphorylation. | Q34583708 | ||
| Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma | Q34664981 | ||
| Genomic Classification of Cutaneous Melanoma | Q34670776 | ||
| A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma | Q34710725 | ||
| Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma | Q34978580 | ||
| Transformation by Hras(G12V) is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition. | Q35044902 | ||
| A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma | Q35073752 | ||
| Low mutational burden of eight genes involved in the MAPK/ERK, PI3K/AKT, and GNAQ/11 pathways in female genital tract primary melanomas. | Q35073876 | ||
| Exome sequencing identifies GRIN2A as frequently mutated in melanoma | Q35179796 | ||
| Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors. | Q35198387 | ||
| PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting | Q35260766 | ||
| Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation. | Q35779541 | ||
| Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on the Brain Distribution of a Novel BRAF Inhibitor: Vemurafenib (PLX4032) | Q36057973 | ||
| The MAPK signalling pathways and colorectal cancer | Q36111490 | ||
| Could BRAF mutations in melanocytic lesions arise from DNA damage induced by ultraviolet radiation? | Q36538084 | ||
| Mechanisms Limiting Distribution of the Threonine-Protein Kinase B-RaFV600E Inhibitor Dabrafenib to the Brain: Implications for the Treatment of Melanoma Brain Metastases | Q36642420 | ||
| Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors | Q36676466 | ||
| NMR-based functional profiling of RASopathies and oncogenic RAS mutations. | Q36712670 | ||
| The dysplastic nevus: from historical perspective to management in the modern era: part II. Molecular aspects and clinical management | Q36752192 | ||
| The dysplastic nevus: from historical perspective to management in the modern era: part I. Historical, histologic, and clinical aspects | Q36762792 | ||
| Targeting mutant NRAS signaling pathways in melanoma | Q36902066 | ||
| Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor | Q36929804 | ||
| RAF265 inhibits the growth of advanced human melanoma tumors | Q37047974 | ||
| Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma | Q37183820 | ||
| Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations | Q37269341 | ||
| Synchronous BRAF(V600E) and MEK inhibition leads to superior control of murine melanoma by limiting MEK inhibitor induced skin toxicity | Q37360534 | ||
| COSMIC: somatic cancer genetics at high-resolution | Q37556877 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | BRAF inhibitors [cytosol] | Q50256226 |
| MAP kinase signaling system | Q71130435 | ||
| P304 | page(s) | 1483 | |
| P577 | publication date | 2019-01-01 | |
| 2019-03-25 | |||
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | International Journal of Molecular Sciences | Q3153277 |
| P1476 | title | Targeting the ERK Signaling Pathway in Melanoma | |
| P478 | volume | 20 |
| Q92133007 | Adipophilin expression in cutaneous malignant melanoma is associated with high proliferation and poor clinical prognosis |
| Q92875429 | ERK1,2 Signalling Pathway along the Nephron and Its Role in Acid-base and Electrolytes Balance |
| Q92211141 | Joint action of miR-126 and MAPK/PI3K inhibitors against metastatic melanoma |
| Q92366887 | Phellinus gilvus‑derived protocatechualdehyde induces G0/G1 phase arrest and apoptosis in murine B16‑F10 cells |
| Q92960597 | Physiologically Relevant Oxygen Concentration (6% O2) as an Important Component of the Microenvironment Impacting Melanoma Phenotype and Melanoma Response to Targeted Therapeutics In Vitro |
| Q89658448 | Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity |
| Q90724875 | Topical 2'-Hydroxyflavanone for Cutaneous Melanoma |
| Q100697602 | Vegetable Oil-basedHybrid Submicron Particles Loaded with JMV5038: A Promising Formulation against Melanoma |
Search more.